{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "19712626",
  "DateCompleted": {
    "Year": "2010",
    "Month": "02",
    "Day": "02"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "09",
    "Day": "17"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng",
      "spa"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1579-2242",
      "JournalIssue": {
        "Volume": "62",
        "Issue": "9",
        "PubDate": {
          "Year": "2009",
          "Month": "Sep"
        }
      },
      "Title": "Revista espanola de cardiologia",
      "ISOAbbreviation": "Rev Esp Cardiol"
    },
    "ArticleTitle": "Long-term bosentan treatment of complex congenital heart disease and Eisenmenger's syndrome.",
    "Pagination": {
      "StartPage": "1046",
      "EndPage": "1049",
      "MedlinePgn": "1046-9"
    },
    "Abstract": {
      "AbstractText": [
        "The BREATHE-5 study demonstrated that bosentan, an oral endothelin receptor antagonist, provides clinical benefits in patients with Eisenmenger's syndrome. As a result, the European Medicines Agency (EMEA) approved its use for this indication. However, follow-up in that study was limited to 16 weeks and patients with complex congenital heart disease were excluded. We assessed the effect of long-term bosentan treatment in 10 patients with complex congenital heart disease and Eisenmenger's syndrome. In the mean clinical follow-up period of 25 months, all patients reached the target dose without developing side effects and without experiencing a change in arterial oxygen consumption at either rest or maximal exercise. Moreover, there were significant changes in clinical parameters: NYHA functional class improved from 3.3+/-0.7 to 2.5+/-0.9 (P=.002) and the 6-minute walk distance increased from 266+/-161 m to 347+/-133 m (P=.015)."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Servicio de Cardiolog\u00eda, Hospital Universitario de Guadalajara, Guadalajara, Espa\u00f1a."
          }
        ],
        "LastName": "D\u00edaz-Caraballo",
        "ForeName": "Eva",
        "Initials": "E"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Gonz\u00e1lez-Garc\u00eda",
        "ForeName": "Ana E",
        "Initials": "AE"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Re\u00f1ones",
        "ForeName": "Margarita",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "S\u00e1nchez-Recalde",
        "ForeName": "Angel",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Garc\u00eda-R\u00edo",
        "ForeName": "Francisco",
        "Initials": "F"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Oliver-Ruiz",
        "ForeName": "Jos\u00e9 M",
        "Initials": "JM"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Spain",
    "MedlineTA": "Rev Esp Cardiol",
    "NlmUniqueID": "0404277",
    "ISSNLinking": "0300-8932"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Endothelin Receptor Antagonists"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Sulfonamides"
    },
    {
      "RegistryNumber": "Q326023R30",
      "NameOfSubstance": "Bosentan"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Bosentan"
    },
    {
      "QualifierName": [
        "complications",
        "drug therapy"
      ],
      "DescriptorName": "Eisenmenger Complex"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Endothelin Receptor Antagonists"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "complications",
        "congenital",
        "drug therapy"
      ],
      "DescriptorName": "Heart Diseases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Sulfonamides"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Time Factors"
    }
  ]
}